Pasquali R, Vicennati V, Calzoni F, Gnudi U, Gambineri A, Ceroni L, Cortelli P, Menozzi R, Sinisi R, Rio G D
Endocrinology Section, Department of Internal Medicine & Gastroenterology, S. Orsola-Malpighi Hospital, Bologna, Italy.
Clin Endocrinol (Oxf). 2000 Apr;52(4):413-21. doi: 10.1046/j.1365-2265.2000.00871.x.
Abdominal obesity is associated with hyper-responsiveness of the hypothalamic-pituitary-adrenocortical (HPA) axis to stimulatory neuropeptides and to stress. Catecholamines are involved in the regulation of the HPA axis, particularly during stress, via alpha-adrenoceptor modulation.
In this study, we investigated the effects of pre-treatment with an alpha2-adrenoceptor agonist, clonidine (2 microg/kg over 10 minutes) and antagonist, yohimbine (0.125 mg/kg bolus, followed by 0. 001 mg/kg/minutes per 90 minutes infusion) on the HPA axis, measured by ACTH and cortisol response to combined CRH (human, 100 microg) plus AVP (0.3 IU) administration, and on noradrenalin (NA) and adrenalin (A) blood levels, in a group of obese women with abdominal (A-BFD) or peripheral (P-BFD) body fat distribution and in nonobese controls.
During the control CRH + AVP test the ACTH but not the cortisol response was higher (P < 0.05) in obese A-BFD women than in controls, with minor and transient variations of NA levels. Neither the control test nor clonidine or yohimbine influenced basal or post CRH + AVP A concentrations. Clonidine pretreatment similarly and significantly decreased NA levels in all women and, compared to the control test, marginally influenced the ACTH response to CRH + AVP. Conversely, during yohimbine infusion NA levels steadily and similarly increased to values more or less double baseline values in all groups. Compared to the control test, however, the ACTH response to the CRH + AVP test performed during yohimbine infusion significantly decreased in the control subjects whereas a tendency to a further increase occurred in the obese groups and, specifically, in the A-BFD group significantly (P < 0.05) more than in the P-BFD group.
This study shows that alpha2-adrenoceptor regulation of the HPA axis is different in obese and nonobese women, particularly in stressed conditions. We suggest that the abnormal ACTH response to CRH + AVP challenge with increased noradrenergic tone may represent a specific pathophysiological aspect of the abnormal response to stress or to other specific stimulatory factors in obese women, particularly those with abdominal body fat distribution.
腹部肥胖与下丘脑 - 垂体 - 肾上腺皮质(HPA)轴对刺激性神经肽和应激的高反应性有关。儿茶酚胺通过α - 肾上腺素能受体调节参与HPA轴的调节,尤其是在应激期间。
在本研究中,我们调查了用α2 - 肾上腺素能受体激动剂可乐定(10分钟内2微克/千克)和拮抗剂育亨宾(0.125毫克/千克推注,随后以0.001毫克/千克/分钟的速度输注90分钟)预处理对HPA轴的影响,通过促肾上腺皮质激素(ACTH)和皮质醇对联合促肾上腺皮质激素释放激素(CRH,人,100微克)加血管加压素(AVP,0.3国际单位)给药的反应来测量,以及对一组腹部(A - BFD)或外周(P - BFD)体脂分布的肥胖女性和非肥胖对照者的去甲肾上腺素(NA)和肾上腺素(A)血药浓度的影响。
在对照CRH + AVP试验期间,肥胖A - BFD女性的ACTH反应高于对照组(P < 0.05),而皮质醇反应无差异,NA水平有轻微和短暂变化。对照试验、可乐定或育亨宾均未影响基础或CRH + AVP后的A浓度。可乐定预处理同样显著降低了所有女性的NA水平,与对照试验相比,对ACTH对CRH + AVP的反应有轻微影响。相反,在育亨宾输注期间,所有组的NA水平稳步且相似地升高至基线值的两倍左右。然而,与对照试验相比,育亨宾输注期间进行的CRH + AVP试验中,对照组的ACTH反应显著降低,而肥胖组有进一步升高的趋势,特别是A - BFD组比P - BFD组显著升高(P < 0.05)。
本研究表明,肥胖和非肥胖女性中HPA轴的α2 - 肾上腺素能受体调节不同,特别是在应激条件下。我们认为,去甲肾上腺素能张力增加时对CRH + AVP刺激的异常ACTH反应可能代表肥胖女性,尤其是腹部体脂分布女性对应激或其他特定刺激因素异常反应的一个特定病理生理方面。